This chart shows the pharmaceutical drugs with the greatest number of patents still in force.
The number of patents covering a drug can be indicative of the value of a drug — more valuable drugs justify the substantial expense of building and maintaining large patent portfolios — but they can also be indicative of a company’s legal or R&D acumen.
One clear way to keep competitors at bay is to surround key drugs with a web of strong patents, making it unlikely there will be any way to work around patents or invalidate a sufficient number of them. A large patent portfolio can also indicate
strong, innovation-oriented R&D, with a focus on securing IP.
The drugs with the most unexpired patents are:
- VASCEPA
- HYSINGLA ER
- IMBRUVICA
- ABILIFY MYCITE KIT
- EVZIO
- EVZIO (AUTOINJECTOR)
- BYDUREON PEN
- AUVI-Q
- XIFAXAN
- AIRDUO DIGIHALER
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
